Litteratur
Hannila-Handelberg T, Toropainen M, Nohynek H, Kuusi M, Mäkitie I. Varusmiesten invasiiviset meningokokkitaudit 2003–2012. Suom Lääkäril 2015;3–4:121-126.
Toropainen M, Nohynek H. Meningokokkitauti Suomessa – kuka tarvitsee rokotteita? (pdf 565 kb) Suom Lääkäril 2020;21:1296-1302.
Surveillance Atlas of Infectious Diseases, ECDC.
Toimenpideohje estolääkityksestä ja rokotuksista meningokokkitapauksissa, THL
Medicinska riskgrupper
Balmer P, Falconer M, McDonald P, et al. Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals. Infect Immun. 2004;72(1):332‐337. doi:10.1128/iai.72.1.332-337.2004.
Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis. 2016;29(4):319‐329. doi:10.1097/QCO.0000000000000279.
Mahler MB, Taur Y, Jean R, Kernan NA, Prockop SE, Small TN. Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(1):145‐149. doi:10.1016/j.bbmt.2011.07.027.
Martinón-Torres F, Bernatowska E, Shcherbina A, et al. Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function. Pediatrics. 2018;142(3):e20174250. doi:10.1542/peds.2017-4250.
McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine.
MMWR Morb Mortal Wkly Rep. 2017;66(27):734‐737. Published 2017 Jul 14. doi:10.15585/mmwr.mm6627e1.
Klein NP, Habanec T, Kosina P, et al. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study. Vaccine. 2018;36(17):2356-2363. doi:10.1016/j.vaccine.2018.02.085.
Ladhani SN, Campbell H, Lucidarme J, et al. Invasive meningococcal disease in patients with complement deficiencies: a case series (2008-2017). BMC Infect Dis. 2019;19(1):522. Published 2019 Jun 14. DOI:10.1186/s12879-019-4146-5.
Souza AR, Maruyama CM, Sáfadi MA, et al. Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease. Vaccine. 2016;34(36):4327-4334. doi:10.1016/j.vaccine.2016.06.072.
4CMenB-vaccin (MenB-4C, Bexsero®)
Bryan P, Seabroke S, Wong J, et al. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study. Lancet Child Adolesc Health. 2018;2(6):395‐403. doi:10.1016/S2352-4642(18)30103-2.
Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–317. DOI:10.1056/NEJMoa1901229.
Martinón-Torres F, Nolan T, Toneatto D, Banzhoff A. Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults. Hum Vaccin Immunother. 2019;15(12):2940-2951. DOI: 10.1080/21645515.2019.1627159.
Muzzi A, Brozzi A, Serino L, et al. Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine. 2019;37(7):991-1000. doi:10.1016/j.vaccine.2018.12.061.
Parikh SR, Andrews NJ, Beebeejaun K ym. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016 Dec 3;388(10061):2775-2782. DOI:10.1016/S0140-6736(16)31921-3.
Prymula R, Esposito S, Zuccotti GV, et al. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I) Effects of prophylactic paracetamol on immunogenicity and reactogenicity of routine infant vaccines and 4CMenB. Hum Vaccin Immunother. 2014;10(7):1993‐2004. doi:10.4161/hv.28666
Vogel U, Taha MK, Vazquez JA ym. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013 May;13(5):416-25. DOI:10.1016/S1473-3099(13)70006-9.
Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381(9869):825-835. doi:10.1016/S0140-6736(12)61961-8.
MenACWY-TT-vaccin (Nimenrix®)
Assaf-Casals A, Dbaibo G. Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence. Hum Vaccin Immunother. 2016 Jul 2;12(7):1825-37. doi: 10.1080/21645515.2016.1143157.
Dhillon S, Pace D. Meningococcal Quadrivalent Tetanus Toxoid Conjugate Vaccine (MenACWY-TT; Nimenrix®): A Review. Drugs. 2017;77(17):1881-1896. doi:10.1007/s40265-017-0828-8.
Findlow H, Borrow R. Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT. Adv Ther. 2013;30(5):431‐458. doi:10.1007/s12325-013-0032-5.
Nolan T, Booy R, Marshall HS, et al. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers. Pediatr Infect Dis J. 2019;38(6):643-650. doi:10.1097/INF.0000000000002334.
Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines. Pediatr Infect Dis J. 2015;34(12):e298-e307. doi:10.1097/INF.0000000000000897.
